Table 2 Change of best corrected visual acuity, height of PED and proportion without PED in each study
Study | Interventions (mg) | Follow-up (months) | Change of BCVA | Change of height of PED | Proportion without PED | |||
|---|---|---|---|---|---|---|---|---|
Average (LogMAR) | Standard deviation | Average (μm) | Standard deviation | Baseline | Last visit | |||
Anagha 2018 [21] | IVR 0.5 | 6 | -0.13 | 0.04 | -107.9 | 25.2 | 0/42 | 17/42 |
IVA 2.0 | 6 | -0.14 | 0.035 | -69.9 | 23.93 | 0/50 | 14/50 | |
Sarraf 2016 [22] | IVR 0.5 | 24 | -0.18 | 0.014 | -155.9 | 15.28 | 0/154 | 82/154 |
IVR 2.0 | 24 | -0.14 | 0.034 | -191.1 | 13.9 | 0/158 | 111/158 | |
Chan 2015 [23] | IVR 0.5 | 12 | -0.11 | 0.122 | -167.6 | 42.66 | NA | NA |
IVR 2.0 | 12 | -0.11 | 0.06 | -245.06 | 32.22 | NA | NA | |
Au 2016 [24] | IVA 2.0 | 12 | 0.03 | 0.108 | -174.53 | 12.12 | NA | NA |
IVR 0.5 | 12 | 0.1 | 0.058 | -78.89 | 16.55 | NA | NA | |
Park 2016 [25] | IVR 0.5 | 12 | -0.19 | 0.041 | -65.44 | 11.61 | NA | NA |
IVA 2.0 | 12 | -0.2 | 0.033 | -84.81 | 12.21 | NA | NA | |
Rouvas 2018 [26] | IVR 0.5 | 12 | -0.03 | 0.032 | -179.48 | 10.56 | NA | NA |
IVA 2.0 | 12 | -0.17 | 0.035 | -226.51 | 9.51 | NA | NA | |
Ulusoy 2021 [27] | IVR 0.5 | 12 | -0.13 | 0.125 | -45.75 | 16.14 | NA | NA |
IVA 2.0 | 12 | -0.21 | 0.084 | -103.16 | 21.8 | NA | NA | |